Canada: The USMCA: What Does It Mean For Patents And The Pharmaceutical Industry?

In a joint statement on September 30, 2018, the United States and Canadian Governments announced that they reached an agreement, alongside Mexico, on a new, modernized trade agreement for the 21st century.1 The pending trilateral deal, called the United States-Mexico-Canada Agreement (USMCA), is intended to replace the North American Free Trade Agreement (NAFTA) currently in force.

The text of the USMCA was published on the Office of the United States Trade Representative website shortly after the formal agreement was announced.2 The deal includes updated provisions governing the protection and enforcement of intellectual property (IP) rights which, if ratified, will modify the legal and regulatory landscape for the pharmaceutical industry in Canada, notably in the field of biologics. The following is a summary of what is new and what will likely remain the same after the USMCA comes into force.


Data Protection – Biologics

Current Data Protection Regime

The current data protection regime in Canada provides legal protection to "innovative drugs" from generic competition for a period of eight years though the protection of innovator data. Canadian law currently defines an "innovative drug" as one that contains a new medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient (e.g. a salt, ester, enantiomer, solvate, or polymorph).3 This definition of innovative drugs includes both biologic and non-biologic drugs.

In the first six years of data protection, a generic manufacture cannot file a drug submission making a direct or indirect comparison to the innovator's data. In the last two years, a drug submission may be filed but the approval cannot issue until the expiry of the eight-year term. Drugs that qualify for data protection are listed on Health Canada's Register of Innovative Drugs.4

Data Protection for Biologics under the USMCA

Under the USMCA, Canada has agreed to extend the term for data protection for new pharmaceutical products that contain a biologic from eight years to at least ten years.5 The text of the USMCA defines a biologic as a product that, at minimum, is "produced using biotechnology processes and that is, or, alternatively, contains, a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, for use in human beings for the prevention, treatment, or cure of a disease or condition".6

The minimum ten-year period will run from the date of first marketing approval of that product in the relevant country.

Patent Term Extension – Patent Granting Authority Delays

The patent term extension provisions of the USMCA provide for an adjustment to a patent term for delays owing to the patent granting authority.7 However, Canada does not currently provide for patent term adjustment for "unreasonable" delays in the issuance of a patent by the Patent Office.8 At this time there is no indication of how long the patent term will be extended over such delays.


Data Protection – Non-Biologics

i. New Pharmaceutical Products

The USMCA prohibits generic manufacturers from referencing undisclosed test or other data concerning safety and efficacy of "new pharmaceutical products" for at least five years from the date marketing approval was first granted.9 Canada's existing regime appears to surpass the minimum outcomes agreed to under the USMCA.10

ii. Previously Approved Pharmaceutical Products

The USMCA also contains a provision for at least three years of data protection for new clinical information submitted for a previously approved pharmaceutical product covering a new indication, formulation, or method of administration.11 However, in a footnote the USMCA provides that if a Party already provides eight years of data protection pursuant to a new pharmaceutical product, which Canada offers, such data protection is optional.

Patent Term Extensions – Regulatory or Marketing Approval for Pharmaceutical Patent Delays

The patent term extension provisions of the USMCA also provide for an adjustment due to "unreasonable curtailment" of a patent term for regulatory or marketing approval for pharmaceutical patents. 12 Since the implementation of the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada already provides up to two years of patent term adjustment as a result of the pharmaceutical marketing approval process. 13

Patentable Subject Matter

According to the text of the USMCA, patents must be granted for inventions that are new, non-obvious, and useful.14 Eligible exclusions for patentable subject matter are: (1) diagnostic, therapeutic, and surgical methods of treatment in humans or animals; (2) animals and plants, other than microorganisms; and, (3) essentially biological processes for the production of plants or animals.15

Patent Linkage and Early Working Exception

The USMCA includes provisions analogous to Canada's early working exception and regulatory regime for challenging pharmaceutical patents under the Patented Medicines (Notice of Compliance) Regulations.16 However, no major changes to the Regulations are expected as a result of the USMCA.


The USMCA does not yet have the force of law. Before coming into force, the agreement will have to be ratified by each country.

Once the USMCA is in force, Canada will have five years to implement its obligations with respect to the ten-year data protection term for biologics and four and a half years to implement its obligations with respect to patent term adjustments for unreasonable granting authority delays.17


1 Global Affairs Canada, Joint Statement from United States Trade Representative Robert Lighthizer and Canadian Foreign Affairs Minister Chrystia Freeland (30 September 2018), online: <>.

2 United States-Mexico-Canada Agreement Text, online: <> [USMCA].

3 Food and Drug Regulations, CRC c 870, C.08.004.1.

4 Health Canada, Register of Innovative Drugs, online: <>.

5 USMCA, supra note 2, Art 20.F.14.1 (a new pharmaceutical product is defined as a pharmaceutical product that does not contain a chemical entity that has been previously approved in the applicable country).

6 Ibid, Art 20.F.14.2.

7 Ibid, Art 20.F.9.

8 Ibid, Art 20.F.9 (under the USMCA, unreasonable delays are defined as more than five years from the date of filing of the application or three years after a request for examination of the application has been made, whichever is later).

9 Ibid, Art 20.F.13.1 (the USMCA defines a "new pharmaceutical product" at Art 20.F.15 as a pharmaceutical product that does not contain a chemical entity that has been previously approved in the applicable country).

10 Since the USMCA defines a "new pharmaceutical" product as one that does not contain a chemical entity that has been previously approved in the applicable country, these products appear to fall within the definition of "innovative drug" in Canada.

11 USMCA, supra note 2, Art 20.F.13.2.

12 Ibid, Art 20.F.11.

13 Certificate of Supplementary Protection Regulations, SOR/2017-165 (Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics, and veterinary drugs).

14 USMCA, supra note 2, Art 20.F.1.1.

15 Ibid, Art 20.F.1.3.

16 Ibid, Art 20.F.16.

17 Ibid, Art 20.K.1.4.

Read the original article on

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions